Multi-dose Phase IIa trial of MPC-7869 in prostate cancer patients with increasing prostate specific antigen

Multi-dose phase I-II trial of E-7869 in prostate cancer patients Safety and time to PSA progression. Proceedings of the American Association for Cancer Research Annual Meeting 42: 142, March, 2001

Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Clinical Genitourinary Cancer 4(4): 287-292, 2006

A phase I/II dose finding trial of the intravenous injection of CV787, a prostate specific antigen-dependent cytolytic adenovirus in patients with advanced hormone refractory prostate cancer. European Journal of Cancer 37(Supplement 6): S217-S218, October, 2001

Phase 1/2 dose escalation trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology 23(16_suppl): 4615-4615, 2016

A phase I/II dose escalation trial of the intra prostatic injection of CG7870, a prostate specific antigen-dependent oncolytic adenovirus in patients with locally recurrent prostate cancer following definitive radiotherapy. Cancer Gene Therapy 10(Supplement 1): S13-S14, January, 2003

Low rectal toxicity after dose escalated IMRT treatment of prostate cancer using an absorbable hydrogel for increasing and maintaining space between the rectum and prostate: results of a multi-institutional phase II trial. RadioTherapy and Oncology 106(2): 215-219, 2013

PK guided multi-dose, tolerance and safety of E-7869 in prostate cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting (41): 609, March, 2000

A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 31(6): 943-949, 2013

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet. Oncology 13(5): 501-508, 2012

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urologic Oncology 34(12): 530.E15-530.E21, 2016

A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62(2): 115-122, 2004

Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clinical Cancer Research 11(20): 7470-7479, 2005

Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. Journal of Urology 158(2): 502-504, 1997

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38(1): 73-78, Jan 1, 1999